J
Jean-Sébastien Hulot
Researcher at University of Paris
Publications - 294
Citations - 19821
Jean-Sébastien Hulot is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Clopidogrel. The author has an hindex of 61, co-authored 260 publications receiving 16922 citations. Previous affiliations of Jean-Sébastien Hulot include Icahn School of Medicine at Mount Sinai & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Gilles Montalescot,Udo Sechtem,Stephan Achenbach,Felicita Andreotti,Chris Arden,Andrzej Budaj,Raffaele Bugiardini,Filippo Crea,Thomas Cuisset,Carlo Di Mario,J. Rafael Ferreira,Bernard J. Gersh,Anselm K. Gitt,Jean-Sébastien Hulot,Nikolaus Marx,Lionel H. Opie,Matthias Pfisterer,Eva Prescott,Frank Ruschitzka,Manel Sabaté,Roxy Senior,David P. Taggart,Ernst E. van der Wall,Christiaan J. Vrints,José Luis Zamorano,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Robert Fagard,Roberto Ferrari,David Hasdai,Arno W. Hoes,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Per Anton Sirnes,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Marco Valgimigli,Marc J. Claeys,Norbert Donner-Banzhoff,Herbert Frank,Christian Funck-Brentano,Oliver Gaemperli,José Ramón González-Juanatey,Michalis Hamilos,Steen Husted,Stefan James,Kari Kervinen,Steen Dalby Kristensen,Aldo P. Maggioni,Axel R. Pries,Francesco Romeo,Lars Rydén,Maarten L. Simoons,Ph. Gabriel Steg,Adam Timmis,Aylin Yildirir +68 more
TL;DR: The If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction is evaluated as well as patients with Diabetes mellitus for Optimal management of Multivessel disease.
Journal ArticleDOI
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet,Jean-Sébastien Hulot,Anna Pena,Eric Villard,Jean-Baptiste Esteve,Johanne Silvain,Laurent Payot,Delphine Brugier,Guillaume Cayla,Farzin Beygui,Gilbert Bensimon,Christian Funck-Brentano,Gilles Montalescot +12 more
TL;DR: The CYP2C19*2 genetic variant is a major determinant of prognosis in young patients who are receiving clopidogrel treatment after myocardial infarction and is the only independent predictor of cardiovascular events.
Journal ArticleDOI
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sébastien Hulot,Alessandra Bura,Eric Villard,Michel Azizi,Véronique Remones,Catherine Goyenvalle,Martine Aiach,Philippe Lechat,Pascale Gaussem +8 more
TL;DR: The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopsinogrel resistance in the clinical setting.
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
TL;DR: In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).
Journal ArticleDOI
Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.
Philippe Lechat,Jean-Sébastien Hulot,Sylvie Escolano,Alain Mallet,Alain Leizorovicz,Marie Werhlen-Grandjean,Gilbert Pochmalicki,Henry J. Dargie +7 more
TL;DR: B HR and HRC are significantly related to prognosis in heart failure and bisoprolol-induced benefit over placebo for survival was observed to a similar extent at any level of both BHR and HRC.